Mirati Therapeutics (MRTX): next trial readout expected around 2026-09-08
$MRTX · Mirati Therapeutics Inc.Trials that could report in the next 12 months: 6BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything MRTX is running — see methodology.
- 2026-09-08in 3wA Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
- 2026-09-30in 6wCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
- 2026-10-30in 10wTrial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
- 2028-02-16in 78wA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- 2028-10-31in 115wPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- 2029-09-07in 159wA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo … | Phase 3 | Recruitingstill enrolling patients | 2029-09-07 | NCT06875310 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrol… | Phase 2 | Recruitingstill enrolling patients | 2028-10-31 | NCT04613596 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Par… | Phase 2 | Recruitingstill enrolling patients | 2028-02-16 | NCT07415031 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutatio… | Phase 2 | Active Not Recruitingenrolled, still running | 2026-10-30 | NCT05853575 |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC W… | Phase 2 | Active Not Recruitingenrolled, still running | 2026-09-30 | NCT05609578 |
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sin… | Phase 1 | Not Yet Recruitingnot open yet | 2026-09-08 | NCT07723118 |
Status-change history
Every ClinicalTrials.gov change recorded for MRTX's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is MRTX's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is MRTX's lead program in?
Phase 3 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.